- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00779363
A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients
A Prospective Clinical Trial of the TANTALUS System In Treatment of Obese to Morbidly Obese Patients
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective multi center, non-randomized, treatment only clinical trial with up to thirty (30) obese with type 2 diabetes subjects. The study is designed to demonstrate that use of the rechargeable TANTALUS II IPG is safe and that it functions as designed.
Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Cedars Sinai
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- Diabetes and Glandular Disease Clinic (DGD)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 21-70 years
- Diabetic subjects having HbA1c greater than or equal to 7.5% and less than or equal to 9.5 % at Visit 1
- Sex: male or female. Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods.
- Type 2 diabetes duration less than 10 years but at least 6 months
- Type 2 diabetic Subjects taking no more than two (2) oral anti-diabetic agents [Sulfonylurea, Metformin or thiazolinedione (TZD)].
- Stable anti-diabetic drugs for at least three (3) months prior to enrollment and six (6) months for thiazolinedione (TZD).
- Fasting blood glucose values > 120 and < 240 mg/dl at baseline
- Stable HbA1c, described as no significant change (≤ 0.5% variation) between a historical value in the subjects' medical record within 3 months prior to enrollment and the A1c value gathered at baseline.
- If subject is under anti-depressant medication, the treatment needs to be stable for at least six (6) months prior to enrollment.
- BMI between 28 and 45 (kg/m2)
- Stable weight, defined as no significant weight change over the three months prior to enrollment as reported by the subject (±5 kg).
- Stable medications (including anti-hypertensive and lipid-lowering) for at least one month prior to enrollment.
- Compliant, willing and able to participate in the follow-up visits for the study duration.
- Alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and personally motivated to abide by the requirements and restrictions of the clinical trial.
- Able to provide voluntary informed consent.
Exclusion Criteria:
- Gastroparesis or intestinal pseudo-obstruction.
- Receiving medications known to affect gastric motility.
- Taking appetite suppressant or weight loss medications within 1 month of enrollment.
- Diabetic subjects on insulin.
- Past or current psychiatric condition that may impair his or her ability to comply with the study procedures.
- Severe eating disorders such as bulimia or binge eating.
- Obese due to a clinically diagnosed endocrine problem.
- Pregnant (proven by positive βhCG), or lactating.
- History of anemia (<10 g/dl) over past 3-months.
- Prior bariatric surgery.
- History of peptic ulcer disease.
- Use of another investigational device or agent in the 30 days prior to enrollment.
- Participation in another clinical study.
- Life threatening co-morbidity or life expectancy of less than one year.
- Myocardial Infarction or one or more episodes of unstable angina within six months prior to enrollment.
- Implanted with a permanent pacemaker, an automatic implantable defibrillator, or other electro-stimulation device.
- History of life threatening disease within 5 years of enrollment.
- Use of routine ulcerogenic drugs.
- Use of prescription, over the counter or herbal weight loss products.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Implanted Device
|
Subjects will undergo an approximately two week baseline screening process.
Eligible subjects will undergo device implantation.
This will be followed by therapy initiation approximately one week after implantation.
The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy.
Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Safety Evaluation
Tidsramme: June 2004-September2009
|
June 2004-September2009
|
Device Functionality Evaluation
Tidsramme: June 2004-September2009
|
June 2004-September2009
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in HbA1c
Tidsramme: June 2004-September2009
|
June 2004-September2009
|
Percentage of body weight loss
Tidsramme: June 2004-September2009
|
June 2004-September2009
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Harold Lebowitz, MD, Proffesor of Medicine, Endocrinology and Metabolism/Diabetes, State University on NY Health Science
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på rechargeable TANTALUS II
-
MetaCure (USA), Inc.FullførtDiabetes mellitus, type 2Østerrike, Tyskland, Italia, Polen
-
MetaCure (USA), Inc.AvsluttetDiabetes mellitus, type 2Tyskland, Tsjekkisk Republikk, Romania
-
MetaCure (USA), Inc.AvsluttetOvervektig | Type 2 diabetes mellitusForente stater
-
Chinese University of Hong KongMetaCure LimitedUkjent
-
Sun Pharmaceutical Industries LimitedMoebius Medical Ltd.; Nordic Bioscience Clinical Development (NBCD)FullførtArtrose i kneForente stater, Danmark, Hong Kong
-
Sohag UniversityRekruttering
-
Guidant CorporationSuspendert
-
University Hospital, MontpellierFullførtAutismespekterforstyrrelser
-
Psychiatric Centre RigshospitaletUniversity of Copenhagen; IT University of CopenhagenFullført
-
Smith & Nephew, Inc.Aktiv, ikke rekrutterende